TG Therapeutics | TGTX - Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Alaunos Therapeutics USD 3.72M 1.01M 2025-09
Amgen USD 90.59B 445M 2025-12
Ardelyx USD 501.6M 15.43M 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
Bayer EUR 104.54B 331M 2025-12
Biogen USD 29.44B 232M 2025-12
Corcept Therapeutics USD 836.65M 13.04M 2025-12
Curis USD 19.97M 9.27M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Infinity Pharmaceuticals USD 21.23M 8.72M 2023-06
J&J USD 199.21B 6.39B 2025-12
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Novavax USD 1.18B 3.38M 2025-12
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
TG Therapeutics USD 1.06B 38.23M 2025-12
Verastem USD 246.44M 69.59M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12